A study analysing incidence rate of venous thromboembolism in patients with type 2 diabetes treated with Sodium-glucose co-transporter 2 inhibitors
Latest Information Update: 22 Dec 2020
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Alpha-glucosidase inhibitors; Biguanides; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide 1 agonist; Meglitinide; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 22 Dec 2020 New trial record
- 11 Dec 2020 Results published in the American Journal of Medicine